Earnings Summary

Castle Biosciences Inc’s revenue jumped 43.92% since last year same period to $50.14Mn in the Q2 2023. On a quarterly growth basis, Castle Biosciences Inc has generated 19.27% jump in its revenue since last 3-months.

Castle Biosciences Inc’s net profit fell -1039.38% since last year same period to $-18.78Mn in the Q2 2023. On a quarterly growth basis, Castle Biosciences Inc has generated 35.7% jump in its net profits since last 3-months.

Castle Biosciences Inc’s net profit margin fell -691.69% since last year same period to -37.45% in the Q2 2023. On a quarterly growth basis, Castle Biosciences Inc has generated 46.09% jump in its net profit margins since last 3-months.

Castle Biosciences Inc’s earning per share (EPS) estimates for the current quarter stand at -0.84 - a 4.55% jump from last quarter’s estimates.

Castle Biosciences Inc’s earning per share (EPS) estimates for the current year stand at -0.84.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Castle Biosciences Inc’s return on assets (ROA) stands at -0.14.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Castle Biosciences Inc’s return on equity (ROE) stands at -0.22.